Fig. 4From: Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?Cost-effectiveness Acceptability Curve A question 1 simulation; B question 2 simulation. SOF Sofosbuvir, VEL Velpatasvir, LDV LedipasivrBack to article page